ReviewAnnals of surgery2025
Assessing Surgical Innovation: ALPPS: An IDEAL Example of Disruptive Innovation.
Review in Annals of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanical hypertrophy versus biological optimization: rethinking the role of ALPPS in the era of systemic therapy.Hepatobiliary surgery and nutrition · 2026Article
- From IDEAL learning curve to team maturation: a decade of experience reducing conversion in laparoscopic liver resection.Surgical endoscopy · 2026Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
Abstract
objectiveTo assess the impact of the IDEAL (innovation, development, exploration, assessment and long-term) paradigm on the development of ALPPS (associating liver partition and portal vein ligation for staged hepatectomy) in comparison to the evaluation of 2 other revolutionary innovations: laparoscopic cholecystectomy (LC) and robotic surgery.
backgroundThe assessment and development of disruptive procedures often follow a chaotic and unstructured approach. The IDEAL paradigm has offered a sequential 5-stage process to assess controversial surgical strategies like ALPPS, which was introduced in 2012 to expand liver surgery for primarily nonresectable disease.
resultsBy October 2024, the international ALPPS registry collected 1349 cases from 146 centers in 46 countries. Early reports unveiled an alarming morbidity and perioperative mortality. Accumulating cases in the registry and a consensus conference enabled to reduce the initial 90-day mortality rates >15% to <5% in high-volume centers. Meta-analyses, long-term follow-up and a RCT were available through the growing data in the registry. In comparison, the development of LC was similarly marked by technical advances and a registry to highlight safety (especially bile duct injuries). A small multicenter RCT (and a larger one later) supported an unstoppable wave of rapid adoption by patients and surgeons. Robotic surgery is currently going through close scrutinization by many stakeholders in view of the massive promotion by the industry, but a compelling registry is still missing.
conclusionsALPPS has now reached a high-level of evaluation with clear guidelines for use thanks to international collaborations and the IDEAL paradigm. This may serve as template for future evaluations of surgical innovations.
Indexed as
Identifiers
40772712What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.